CLAIMS

1. *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine (AZD9833) for use in the treatment of cancer, wherein the AZD9833 is to be administered orally once daily at a dose of 75 mg or 150 mg.

2. AZD9833 for use according to claim 1, wherein the AZD9833 is to be administered as a single dose unit or as multiple dose units.

3. AZD9833 for use according to claim 2, wherein the AZD9833 is to be administered as a single tablet.

4. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is to be administered in combination with a further anti-cancer therapy.

5. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is to be administered in combination with palbociclib.

6. AZD9833 for use according to any of claims 1 to 4, wherein the AZD9833 is to be administered in combination with an mTOR inhibitor.

7. AZD9833 for use according to claim 6, wherein the AZD9833 is to be administered in combination with everolimus.

8. AZD9833 for use according to any of the preceding claims, wherein the cancer is selected from breast cancer and gynaecological cancer.

9. AZD9833 for use according to claim 8, wherein the cancer is ER-positive HER2-negative advanced breast cancer.

10. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is to be administered to a pre- or post-menopausal woman.

11. AZD9833 for use according to any of the preceding claims, wherein the cancer has previously been treated with ≥1 endocrine therapy and ≤2 prior chemotherapies for ER-positive HER2-negative advanced breast cancer.

12. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is to be administered to a patient whose cancer is resistant to non-steroidal aromatase inhibitors.

13. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 i) is capable of achieving a mean peak blood plasma concentration in a cancer patient of between 10 and 1000 ng/mL; and/or ii) is capable of achieving a median terminal half-life between 8h and 14h in a cancer patient; and/or iii) is capable of achieving a median terminal half-life of 12h in a cancer patient.

14. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 is capable of achieving an objective response rate of at least 10%.

15. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 does not cause any serious side-effects in a cancer patient.

16. Use of AZD9833 in the manufacture of a medicament for treating cancer in a human or animal patient in need of such treatment, wherein AZD9833 is to be administered to the patient orally once daily at a dose of 75 mg or 150 mg.

17. Use of AZD9833 in the manufacture of a medicament for the treatment of cancer, wherein the AZD9833 is to be administered orally once daily at a dose between 75 mg and 150 mg.

18. A pharmaceutical composition for once daily oral administration comprising between 75 mg and 150 mg of AZD9833 and a pharmaceutically acceptable excipient.

19. A pharmaceutical composition according to claim 18, wherein the amount of AZD9833 is selected from 25 mg, 75 mg and 150 mg.

20. A pharmaceutical composition according to claim 18 or claim 19 in the form of a single tablet.

21. A pharmaceutical composition according to any of claims 18 to 20 for use in the treatment of cancer.

22. A kit comprising a pharmaceutical composition comprising AZD9833 and at least one pharmaceutically acceptable excipient and instructions for the use of the pharmaceutical

composition in the treatment of cancer, wherein the AZD9833 is for once daily administration at a dose of 75 mg and 150 mg.

23. A kit according to claim 22, further comprising an additional anti-cancer agent for administration in combination with AZD9833.

24. The use according to claim 17, wherein the AZD9833 is to be administered as a single dose unit or as multiple dose units.

25. The use according to claim 24, wherein the AZD9833 is to be administered as a single tablet.

26. The use according to any of claims 17 and 24-25, wherein the AZD9833 is to be administered in combination with a further anti-cancer therapy.

27. The use according to any of claims 17 and 24-26, wherein the AZD9833 is to be administered in combination with palbociclib.

28. The use according to any of claims 17 and 24-26, wherein the AZD9833 is to be administered in combination with an mTOR inhibitor.

29. The use according to claim 28, wherein the AZD9833 is to be administered in combination with everolimus.

30. The use according to any of claims 17 and 24-29, wherein the cancer is selected from breast cancer and gynaecological cancer.

31. The use according to claim 30, wherein the cancer is ER-positive HER2-negative advanced breast cancer.

32. The use according to any of claims 17 and 24-31, wherein the AZD9833 is to be administered to a pre- or post-menopausal woman.

33. The use according to any of claims 17 and 24-32, wherein the cancer has previously been treated with ≥1 endocrine therapy and ≤2 prior chemotherapies for ER-positive HER2-negative advanced breast cancer.

34. The use according to any of claims 17 and 24-33, wherein the AZD9833 is to be administered to a patient whose cancer is resistant to non-steroidal aromatase inhibitors.

35. The use according to any of claims 17 and 24-34, wherein the dose of AZD9833 i) is capable of achieving a mean peak blood plasma concentration in a cancer patient of between 10 and 1000 ng/mL; and/or ii) is capable of achieving a median terminal half-life between 8h and 14h in a cancer patient; and/or iii) is capable of achieving a median terminal half-life of 12h in a cancer patient.

36. The use according to any of claims 17 and 24-35, wherein the dose of AZD9833 is capable of achieving an objective response rate of at least 10%.

37. The use according to any of claims 17 and 24-36, wherein the dose of AZD9833 does not cause any serious side-effects in a cancer patient.